Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Burn wound eschar is a dry, thick, often black or brown piece of necrotic tissue that forms on the surface of the skin following a severe burn or other devitalizing injury. It is not the same as a scab (dried blood and exudate) but represents dead and devitalized skin and subcutaneous tissue, sometimes acting as a physical barrier to wound healing and increasing the risk of infection. Eschar may be allowed to slough naturally or require removal by surgical (debridement, escharotomy), enzymatic, mechanical, or autolytic means if infection or compromised circulation is suspected. Eschar is an important clinical finding in burn medicine and wound care, but it is not an individual molecular or cellular target for drug action.
Antimicrobials prevent or treat infection in tissue beneath or surrounding eschar. Enzymatic debridement facilitates breakdown/removal of necrotic tissue. Surgical debridement or escharotomy physically removes the eschar to restore blood flow, relieve pressure, or access healthy tissue.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Burn wound eschar.